Antihypertensive medications

Current status of angiotensin receptor blocker recalls

Our analysis of data from FDA's assessment of currently marketed angiotensin receptor blocker drugs, with regard to nitrosamine impurities


We review the recent guidelines addressing the diagnosis and management of hypertension.

Hypertension hot potato — anatomy of the angiotensin-receptor blocker recalls

We provide insights into the effects of recent blood pressure medication recalls on patients, healthcare providers, and health systems.

Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism

**Context:** Many antihypertensive medications modulate the renin-angiotensin-aldosterone system, possibly skewing the diagnosis and subtyping of primary aldosteronism (PA). Particularly, mineralocorticoid receptor antagonists (MRA) might raise renin …

Pharmacologic treatment of hypertension

Combination therapy as initial treatment for newly diagnosed hypertension

**BACKGROUND:** The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends that clinicians consider the use of multidrug therapy to increase likelihood of achieving blood …

Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use

**BACKGROUND:** Immunosuppressants decrease circulating dipeptidyl peptidase IV (DPPIV) activity in transplant patients, and decreased DPPIV activity has been associated with angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. One …

Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema

**BACKGROUND:** Angioedema is a rare adverse effect of angiotensin-converting enzyme (ACE) inhibitors, which occurs more commonly in women and black Americans. Angioedema is thought to result from decreased degradation of vasoactive peptides. During …

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema

Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals. …